FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Coleman

Research Profile

Chemicals & Drugs

Disorders

Physiology

Bone Resorption

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Robin J Young; Robert E Coleman
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Robert E Coleman
Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Penelope D Ottewell; Thea L Rogers; Mark Jones; Hannah K Brown; Nicola J Brown; Robert E Coleman; Simon S Cross; Ingunn Holen
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Coleman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robin J Young; Robert E Coleman
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Future oncology (London, England) 2013;9(5):633-43.
2012: Robert E Coleman
Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Current opinion in supportive and palliative care 2012;6(3):322-9.
2012: Penelope D Ottewell; Thea L Rogers; Mark Jones; Hannah K Brown; Nicola J Brown; Robert E Coleman; Simon S Cross; Ingunn Holen
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Breast cancer research and treatment 2012;133(2):523-36.
2012: Robert E Coleman; A L Jones; I Kunkler; D Miles; P D Simmonds; T Beaumont; G Bertelli; I E Smith
UK guidance document: treatment of metastatic breast cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2012;24(3):169-76.
2011: E Arden-Close; Robert E Coleman; Christine Eiser; D M Greenfield; Barry W Hancock; Kate Absolom
Gender differences in self-reported late effects, quality of life and satisfaction with clinic in survivors of lymphoma.
Psycho-oncology 2011;20(11):1202-10.
2011: Robert E Coleman; Claire Davies; David Dodwell; Claire Gaunt; Miguel Gil; Walter Gregory; Robert J Grieve; Victoria Hiley; Stephen J Houston; Maccon Keane; Helen Marshall; Jennifer Peterson; Julia Pugh; Una Rea; Diana Ritchie; Peter J Barrett-Lee; Richard Bell; Roger Burkinshaw; David Cameron
Breast-cancer adjuvant therapy with zoledronic acid.
The New England journal of medicine 2011;365(15):1396-405.
2011: Robert E Coleman; Eugene V McCloskey
Bisphosphonates in oncology.
Bone 2011;49(1):71-6.
2011: L Walkington; J Webster; Barry W Hancock; J Everard; Robert E Coleman
Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.
British journal of cancer 2011;104(11):1665-9.
2011: Ana Munoz; J Adams; Glen Clack; A Howell; Jack Cuzick; J Mackey; M W Beckmann; Robert E Coleman
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(4):857-62.
2011: Hannah K Brown; Penelope D Ottewell; Robert E Coleman; Ingunn Holen
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.
Journal of cellular and molecular medicine 2011;15(3):501-13.
2011: L Walkington; Robert E Coleman
Advances in management of bone disease in breast cancer.
Bone 2011;48(1):80-7.
2010: Robert E Coleman; Linda M Banks; Samia I Girgis; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Judith M Bliss; R Charles Coombes; Lucy S Kilburn
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Breast cancer research and treatment 2010;124(1):153-61.
2010: James Michael Price; Barry W Hancock; John Tidy; Jan Everard; Robert E Coleman
Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia.
The Journal of reproductive medicine 2010;55(7-8):301-4.
2010: Helen L Neville-Webbe; Michael Gnant; Robert E Coleman
Potential anticancer properties of bisphosphonates.
Seminars in oncology 2010;37 Suppl 1():S53-65.
2010: S G Coulson; V S Kumar; I M Manifold; Matthew Q Hatton; S Ramakrishnan; K S Dunn; Om-Prakesh Purohit; C Bridgewater; Robert E Coleman
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
Clinical oncology (Royal College of Radiologists (Great Britain)) 2010;22(4):289-93.
2010: Omar S Din; David Dodwell; Richard J Wakefield; Robert E Coleman
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Breast cancer research and treatment 2010;120(3):525-38.
2010: Robert E Coleman; M C Winter; D Cameron; R Bell; David Dodwell; M M Keane; M Gil; D Ritchie; J L Passos-Coelho; D Wheatley; Roger Burkinshaw; S J Marshall; H Thorpe
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
British journal of cancer 2010;102(7):1099-105.
2010: Helen L Neville-Webbe; Robert E Coleman; I Holen
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
British journal of cancer 2010;102(6):1010-7.
2010: Diana M Greenfield; Stephen J Walters; Robert E Coleman; Barry W Hancock; John A Snowden; Stephen M Shalet; Leonard R DeRogatis; Richard J M Ross
Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study.
Cancer 2010;116(6):1592-601.
2010: Penelope D Ottewell; Diane V Lefley; Simon S Cross; C Alyson Evans; Robert E Coleman; Ingunn Holen
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
International journal of cancer. Journal international du cancer 2010;126(2):522-32.
2010: Ingunn Holen; Robert E Coleman
Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.
Breast cancer research : BCR 2010;12(6):214.
2010: Maria Michailidou; Hannah K Brown; Diane V Lefley; Alyson Evans; Simon S Cross; Robert E Coleman; Nicola J Brown; Ingunn Holen
Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?
Journal of vascular research 2010;47(6):481-93.
2010: Ingunn Holen; Robert E Coleman
Bisphosphonates as treatment of bone metastases.
Current pharmaceutical design 2010;16(11):1262-71.
2009: Matthew C Winter; Robert E Coleman
Bisphosphonates in breast cancer: teaching an old dog new tricks.
Current opinion in oncology 2009;21(6):499-506.
2009: Penelope D Ottewell; Julia K Woodward; Diane V Lefley; C Alyson Evans; Robert E Coleman; Ingunn Holen
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Molecular cancer therapeutics 2009;8(10):2821-32.
2009: D M Greenfield; K Absolom; Christine Eiser; S J Walters; G Michel; Barry W Hancock; J A Snowden; Robert E Coleman
Follow-up care for cancer survivors: the views of clinicians.
British journal of cancer 2009;101(4):568-74.
2009: Kate Absolom; Christine Eiser; G Michel; Stephen J Walters; Barry W Hancock; Robert E Coleman; John A Snowden; D M Greenfield
Follow-up care for cancer survivors: views of the younger adult.
British journal of cancer 2009;101(4):561-7.
2009: Robert E Coleman
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
European journal of cancer (Oxford, England : 1990) 2009;45(11):1909-15.
2009: Robert E Coleman
Advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence Guideline 2009 - an opportunity missed.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2009;21(5):365-7.
2008: Robert E Coleman; Theresa A Guise; Allan Lipton; David G Roodman; James R Berenson; Jean-Jacques Body; Brendan F Boyce; Laura M Calvi; Peyman Hadji; Eugene McCloskey; Fred Saad; Matthew R Smith; Larry J Suva; Russell S Taichman; Robert L Vessella; Katherine N Weilbaecher
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6387-95.
2008: James E Lester; David Dodwell; Om-Prakesh Purohit; Sandra A Gutcher; Susan P Ellis; Ruth Thorpe; Janet M Horsman; Janet E Brown; Rosemary A Hannon; Robert E Coleman
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):6336-42.
2008: J M Zekri; L M El-Helw; Om-Prakesh Purohit; M Q Hatton; Robert E Coleman
Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2008;20(7):513-6.
2008: Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Journal of the National Cancer Institute 2008;100(16):1167-78.
2008: M C Winter; Ingunn Holen; Robert E Coleman
Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
Cancer treatment reviews 2008;34(5):453-75.
2008: Penelope D Ottewell; Blandine Deux; Hannu Mönkkönen; Simon Cross; Robert E Coleman; Philippe Clezardin; Ingunn Holen
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4658-66.
2008: Robert E Coleman
Risks and benefits of bisphosphonates.
British journal of cancer 2008;98(11):1736-40.
2008: Robert E Coleman; W W Bolten; M Lansdown; S Dale; C Jackisch; D Merkel; N Maass; P Hadji
Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Cancer treatment reviews 2008;34(3):275-82.
2008: Ana Munoz; Judith E Adams; Robert E Coleman; Anthony Howell; Rosemary A Hannon; Jack Cuzick; John R Mackey; Matthias W Beckmann; Glen Clack
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1051-7.
2008: Robert E Coleman; Jean-Jacques Body; Julie R Gralow; Allan Lipton
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Cancer treatment reviews 2008;34 Suppl 1():S31-42.
2007: Julia K L Woodward; Ingunn Holen; Robert E Coleman; David J Buttle
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.
Bone 2007;41(6):912-27.
2007: Robert E Coleman
The benefits and costs of bisphosphonates.
The journal of supportive oncology 2007;5(10):483-4.
2007: Janet E Brown; Eugene McCloskey; J A Dewar; J J Body; D A Cameron; A N Harnett; M Ruutu; Om-Prakesh Purohit; R Tähtelä; Robert E Coleman
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Calcified tissue international 2007;81(5):341-51.
2007: Janet E Brown; Susan P Ellis; James E Lester; Sandra A Gutcher; Tina Khanna; Om-Prakesh Purohit; Eugene McCloskey; Robert E Coleman
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5406-10.
2007: D M Greenfield; Stephen J Walters; Robert E Coleman; Barry W Hancock; Ana Munoz; HA Davies; John A Snowden; L Derogatis; S M Shalet; R J M Ross
Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study.
The Journal of clinical endocrinology and metabolism 2007;92(9):3476-82.
2007: Robert E Coleman; Linda M Banks; Samia I Girgis; Lucy S Kilburn; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Claire F Snowdon; Emma Hall; Judith M Bliss; R Charles Coombes
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
The lancet oncology 2007;8(2):119-27.
2006: Janet E Brown; Susan P Ellis; Paul Silcocks; Aubrey Blumsohn; Sandra A Gutcher; Clare Radstone; Barry W Hancock; Matthew Q Hatton; Robert E Coleman
Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6480-6.
2006: Simon Cross; Zhiyong Yang; Nicola J Brown; Sabapathy P Balasubramanian; Catherine A Evans; Julia K L Woodward; Helen L Neville-Webbe; Jennifer M Lippitt; M W R Reed; Robert E Coleman; Ingunn Holen
Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
International journal of cancer. Journal international du cancer 2006;118(8):1901-8.
2006: Penelope D Ottewell; Robert E Coleman; Ingunn Holen
From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.
Breast cancer research and treatment 2006;96(2):101-13.
2006: D M Greenfield; J Wright; Janet E Brown; Barry W Hancock; HA Davies; L O'Toole; Christine Eiser; Robert E Coleman; R J M Ross
High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.
British journal of cancer 2006;94(4):469-72.
2006: J E Lester; David Dodwell; Janet M Horsman; S Mori; Robert E Coleman
Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom.
British journal of cancer 2006;94(1):30-5.
2006: Robert E Coleman
The role of bone markers in metastatic bone disease.
Cancer treatment reviews 2006;32 Suppl 1():1-2.
2006: Helen L Neville-Webbe; Catherine A Evans; Robert E Coleman; Ingunn Holen
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2006;27(2):92-103.
2006: Catherine Van Poznak; Simon Cross; M Saggese; Clifford Hudis; Katherine S Panageas; Larry Norton; Robert E Coleman; Ingunn Holen
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Journal of clinical pathology 2006;59(1):56-63.
2005: Julia K L Woodward; Helen L Neville-Webbe; Robert E Coleman; Ingunn Holen
Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.
Anti-cancer drugs 2005;16(8):845-54.
2005: Ingunn Holen; Simon Cross; Helen L Neville-Webbe; Neil A Cross; Sabapathy P Balasubramanian; Peter I Croucher; Catherine A Evans; Jennifer M Lippitt; Robert E Coleman; Colby L Eaton
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
Breast cancer research and treatment 2005;92(3):207-15.
2005: Robert E Coleman; Pierre Major; Allan Lipton; Janet E Brown; Ker-Ai Lee; Matthew Smith; Fred Saad; Ming Zheng; Yong Jiang Hei; John Seaman; Richard Cook
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4925-35.
2005: L El-Helw; Robert E Coleman
Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours.
Cancer treatment reviews 2005;31(3):197-209.
2005: Helen L Neville-Webbe; Amin Rostami-Hodjegan; Catherine A Evans; Robert E Coleman; Ingunn Holen
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
International journal of cancer. Journal international du cancer 2005;113(3):364-71.
2005: Janet E Brown; Richard J Cook; Pierre Major; Allan Lipton; Fred Saad; Matthew Smith; Ker-Ai Lee; Ming Zheng; Yong Jiang Hei; Robert E Coleman
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Journal of the National Cancer Institute 2005;97(1):59-69.
2005: Julia K L Woodward; Robert E Coleman; Ingunn Holen
Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.
Anti-cancer drugs 2005;16(1):11-9.
2004: M Pezeshki; Barry W Hancock; Paul Silcocks; Janet E Everard; J Coleman; Alan Gillespie; John Tidy; Robert E Coleman
The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease.
Gynecologic oncology 2004;95(3):423-9.
2004: Helen L Neville-Webbe; Neil A Cross; Colby L Eaton; R Nyambo; Catherine A Evans; Robert E Coleman; Ingunn Holen
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis.
Breast cancer research and treatment 2004;86(3):269-79.
2004: Janet E Brown; Helen Neville-Webbe; Robert E Coleman
The role of bisphosphonates in breast and prostate cancers.
Endocrine-related cancer 2004;11(2):207-24.
2004: Robert E Coleman
Hormone- and chemotherapy-induced bone loss in breast cancer.
Oncology (Williston Park, N.Y.) 2004;18(5 Suppl 3):16-20.
2004: R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per Eystein Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
The New England journal of medicine 2004;350(11):1081-92.
2004: neeraj bhala; J M Coleman; Clare Radstone; Janet M Horsman; J George; Barry W Hancock; M Q Hatton; Robert E Coleman
The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(1):40-7.
2004: Robert E Coleman
Bisphosphonates: clinical experience.
The oncologist 2004;9 Suppl 4():14-27.
2004: Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Cancer 2004;100(1):36-43.
2003: F Khan; Janet E Everard; S Ahmed; Robert E Coleman; M Aitken; Barry W Hancock
Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects.
British journal of cancer 2003;89(12):2197-201.
2003: Janet E Brown; C S Thomson; Susan P Ellis; Sandra A Gutcher; Om-Prakesh Purohit; Robert E Coleman
Bone resorption predicts for skeletal complications in metastatic bone disease.
British journal of cancer 2003;89(11):2031-7.
2003: Lee S Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Mackey; Justus Apffelstaedt; Mohamad A Hussein; Robert E Coleman; Dirk Reitsma; Bee-Lian Chen; John Seaman
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Cancer 2003;98(8):1735-44.
2003: H l Neville-Webbe; Robert E Coleman
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Palliative medicine 2003;17(6):539-53.
2003: Colby L Eaton; Robert E Coleman
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment.
Cancer treatment reviews 2003;29(3):189-98.
2002: Helen L Neville-Webbe; Ingunn Holen; Robert E Coleman
The anti-tumour activity of bisphosphonates.
Cancer treatment reviews 2002;28(6):305-19.
2002: Janet E Brown; Robert E Coleman
Assessment of the effects of breast cancer on bone and the response to therapy.
Breast (Edinburgh, Scotland) 2002;11(5):375-85.
2002: Janet E Brown; Robert E Coleman
The present and future role of bisphosphonates in the management of patients with breast cancer.
Breast cancer research : BCR 2002;4(1):24-9.
2001: S P Jagdev; P Purohit; S Heatley; C Herling; Robert E Coleman
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1433-8.
2001: Robert E Coleman
Should bisphosphonates be the treatment of choice for metastatic bone disease?
Seminars in oncology 2001;28(4 Suppl 11):35-41.
2001: Robert E Coleman
Metastatic bone disease: clinical features, pathophysiology and treatment strategies.
Cancer treatment reviews 2001;27(3):165-76.
2001: S P Jagdev; Robert E Coleman; Claire M Shipman; A Rostami-H; Peter I Croucher
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
British journal of cancer 2001;84(8):1126-34.
2000: John Tidy; Alan Gillespie; N Bright; Clare Radstone; Robert E Coleman; Barry W Hancock
Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy.
Gynecologic oncology 2000;78(3 Pt 1):309-12.
2000: A M Gillespie; TJ Broadhead; S Y Chan; J Owen; A P Farnsworth; M Sopwith; Robert E Coleman
Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(6):735-41.
2000: Robert E Coleman; A Howell; S P Eggleton; S J Maling; D W Miles
Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):541-6.
2000: LS Dobson; P C Lorigan; Robert E Coleman; Barry W Hancock
Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
British journal of cancer 2000;82(9):1547-52.
2000: A M Gillespie; D Liyim; John R Goepel; Robert E Coleman; Barry W Hancock
Placental site trophoblastic tumour: a rare but potentially curable cancer.
British journal of cancer 2000;82(6):1186-90.
2000: Robert E Coleman
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Breast cancer (Tokyo, Japan) 2000;7(4):361-9.
2000: Robert E Coleman
Management of bone metastases.
The oncologist 2000;5(6):463-70.
2000: Robert E Coleman
Uses and abuses of bisphosphonates.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():179-84.
1999: S Sharma; S Jagdev; Robert E Coleman; Barry W Hancock; P C Lorigan
Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis.
British journal of cancer 1999;81(6):1037-41.
1999: A M Gillespie; Robert E Coleman
The potential of melanoma antigen expression in cancer therapy.
Cancer treatment reviews 1999;25(4):219-27.
1999: Robert E Coleman; Om-Prakesh Purohit; C Black; JJ Vinholes; K Schlosser; H Huss; K J Quinn; John A Kanis
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):311-6.
1999: LS Dobson; Alan Gillespie; Robert E Coleman; Barry W Hancock
The presentation and management of post-partum choriocarcinoma.
British journal of cancer 1999;79(9-10):1531-3.
1998: Alan Gillespie; S Rodgers; A P Wilson; John Tidy; Robert C Rees; Robert E Coleman; Anna K Murray
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue.
British journal of cancer 1998;78(6):816-21.
1998: Robert E Coleman; S Houston; Om-Prakesh Purohit; R D Rubens; A Kandra; J Ford
A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
European journal of cancer (Oxford, England : 1990) 1998;34(6):820-4.
1998: Robert E Coleman
Monitoring of bone metastases.
European journal of cancer (Oxford, England : 1990) 1998;34(2):252-9.
1998: J M Coleman; Robert E Coleman; A R Turner; Clare Radstone; A E Champion
The management and clinical course of testicular seminoma: 15 years' experience at a single institution.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1998;10(4):237-41.
1998: Robert E Coleman; P Smith; R D Rubens
Clinical course and prognostic factors following bone recurrence from breast cancer.
British journal of cancer 1998;77(2):336-40.
1997: JJ Vinholes; Om-Prakesh Purohit; M E Abbey; Ana Munoz; Robert E Coleman
Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1243-50.
1997: Robert E Coleman; Om-Prakesh Purohit; JJ Vinholes; J Zekri
High dose pamidronate: clinical and biochemical effects in metastatic bone disease.
Cancer 1997;80(8 Suppl):1686-90.
1997: Robert E Coleman
Skeletal complications of malignancy.
Cancer 1997;80(8 Suppl):1588-94.
1997: Alan Gillespie; P C Lorigan; Clare Radstone; J C Waterhouse; Robert E Coleman; Barry W Hancock
Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.
British journal of cancer 1997;76(10):1382-6.
1997: JJ Vinholes; C Y Guo; Om-Prakesh Purohit; Ana Munoz; Robert E Coleman
Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):131-8.
1996: P C Lorigan; andy grierson; John R Goepel; Robert E Coleman; M H Goyns
Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA.
Cancer letters 1996;104(1):27-30.
1996: JJ Vinholes; C Y Guo; Om-Prakesh Purohit; Ana Munoz; Robert E Coleman
Metabolic effects of pamidronate in patients with metastatic bone disease.
British journal of cancer 1996;73(9):1089-95.
1996: Robert E Coleman; Om-Prakesh Purohit; JJ Vinholes
The future of bisphosphonates in cancer.
Acta oncologica (Stockholm, Sweden) 1996;35 Suppl 5():23-9.
1996: E Sheridan; P C Lorigan; John R Goepel; D J Radstone; Robert E Coleman
Small cell carcinoma of the cervix.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1996;8(2):102-5.
1995: Om-Prakesh Purohit; C R Radstone; C Anthony; John A Kanis; Robert E Coleman
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
British journal of cancer 1995;72(5):1289-93.
1994: Om-Prakesh Purohit; C Anthony; C R Radstone; J Owen; Robert E Coleman
High-dose intravenous pamidronate for metastatic bone pain.
British journal of cancer 1994;70(3):554-8.
1994: N P O'Rourke; Eugene McCloskey; S Rosini; Robert E Coleman; John A Kanis
Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).
British journal of cancer 1994;69(5):914-7.
1993: Robert E Coleman; Om-Prakesh Purohit
Osteoclast inhibition for the treatment of bone metastases.
Cancer treatment reviews 1993;19(1):79-103.